Recent advances and novel treatment paradigms in acute lymphocytic leukemia.
This is an exciting time in the treatment of acute lymphoblastic leukemia (ALL) given the advances in the relapsed/refractory setting. The development of antibody treatments (including antibody drug conjugates with toxins) offers a different treatment approach compared with conventional chemotherapy regimens. Moreover, the use of bispecific T-cell-engager antibodies (BiTEs) such as blinatumomab harness the cytotoxic activity of T cells against CD19-positive lymphoblasts. Another strategy involves the use of chimeric antigen receptor (CAR) T cells. CAR T cells have demonstrated promising results in the relapsed/refractory setting. However, the use of BiTEs and CAR T cells is also associated with a distinct set of adverse reactions that must be taken into account by the treating physician. Apart from the above strategies, the use of other targeted therapies has attracted interest. Namely, the discovery of the Philadelphia (Ph)-like signature in children and young adults with ALL has led to the use of tyrosine kinase inhibitors (TKI) in these patients. The different drugs and strategies that are being tested in the relapsed/refractory ALL setting pose a unique challenge in identifying the optimum sequence of treatment and determining which approaches should be considered for frontline treatment.
Taussig Cancer Center, Cleveland Clinic Foundation, USA.
Nikolaos
N
Papadantonakis
Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44120, USA.
Anjali S
AS
Advani
blinatumomab; chimeric antigen receptor; immunoconjugates; immunotherapy; inotuzumab; leukemia; relapsed/refractory
Leukemia. 2003 Feb;17(2):334-8
12592332
Pediatr Blood Cancer. 2015 Jun;62(6):964-9
25728039
Immunology. 2009 Oct;128(2):260-70
19740383
Blood. 2007 Feb 1;109(3):944-50
17032921
Cancer. 2013 Aug 1;119(15):2728-36
23633004
Clin Cancer Res. 2004 May 15;10(10):3371-6
15161691
Cancer Res. 2006 Nov 15;66(22):10995-1004
17108138
Am Soc Clin Oncol Educ Book. 2015;:e343-51
25993195
Expert Opin Biol Ther. 2014 Jan;14(1):37-49
24261468
N Engl J Med. 2011 Aug 25;365(8):725-33
21830940
Int J Gen Med. 2015 Jun 12;8:211-4
26109875
Nat Rev Clin Oncol. 2015 Jun;12(6):344-57
25781572
Leuk Res. 1998 Feb;22(2):185-91
9593475
Mol Ther. 2009 Aug;17(8):1453-64
19384291
Leukemia. 2001 Sep;15(9):1388-97
11516099
Blood. 2012 Oct 25;120(17):3510-8
22955920
Blood. 2015 Aug 13;126(7):833-41
25966987
Trends Pharmacol Sci. 2014 Aug;35(8):414-22
24975478
N Engl J Med. 2014 Oct 16;371(16):1507-17
25317870
Lancet. 2015 Feb 7;385(9967):517-528
25319501
J Clin Oncol. 2009 Feb 20;27(6):911-8
19124805
Immunol Rev. 2014 Jan;257(1):107-26
24329793
Hematology Am Soc Hematol Educ Program. 2013;2013:118-25
24319172
Cancer Cell. 2016 Feb 8;29(2):186-200
26859458
Nucleic Acids Res. 2015 Mar 11;43(5):2590-602
25690899
Prog Mol Biol Transl Sci. 2012;109:161-226
22727422
Discov Med. 2011 Dec;12(67):471-80
22204764
Leuk Lymphoma. 2015;56(8):2296-300
25495170
Blood. 2000 Mar 15;95(6):2098-103
10706880
Int J Cancer. 2002 Aug 20;100(6):690-7
12209608
Proc Natl Acad Sci U S A. 2012 May 1;109(18):6898-903
22509046
Expert Opin Biol Ther. 2010 Mar;10(3):439-49
20109133
J Clin Oncol. 2014 Dec 20;32(36):4134-40
25385737
Haematologica. 2015 Apr;100(4):e128-31
25552705
Clin Cancer Res. 2012 Jun 1;18(11):3008-14
22474318
Sci Transl Med. 2013 Mar 20;5(177):177ra38
23515080
Front Biosci (Elite Ed). 2014 Jan 01;6(1):40-5
24389139
Br J Haematol. 2011 Aug;154(4):471-6
21732928
Acta Haematol. 2013;129(4):207-14
23295437
DNA Cell Biol. 2006 Jan;25(1):19-24
16405397
Clin Cancer Res. 2013 Apr 1;19(7):1795-805
23426279
Bioconjug Chem. 1996 Sep-Oct;7(5):557-63
8889017
Eur J Haematol. 2013 Oct;91(4):315-21
23738686
Lancet Oncol. 2009 Feb;10(2):125-34
19138562
Br J Haematol. 2014 May;165(4):504-9
24579885
Blood. 2008 Nov 15;112(10):3982-8
18780832
Blood. 2006 Feb 1;107(3):1116-23
16195338
Br J Haematol. 2010 Aug;150(3):352-8
20528877
Br J Haematol. 2010 Dec;151(5):430-4
21113977
Curr Hematol Malig Rep. 2013 Jun;8(2):91-7
23559026
Immunopharmacology. 1997 Oct;37(2-3):117-32
9403331
Curr Treat Options Oncol. 2004 Aug;5(4):283-8
15233905
Leukemia. 2000 May;14(5):853-8
10803517
Science. 1988 May 27;240(4856):1198-201
3240341
J Clin Oncol. 2013 Sep 1;31(25):e413-6
23835704
Leuk Lymphoma. 2006 Nov;47(11):2380-7
17107913
Clin Cancer Res. 2004 Dec 15;10(24):8620-9
15623646
Am J Hematol. 2015 Mar;90(3):193-6
25407953
Curr Cancer Drug Targets. 2014;14(6):517-36
25092212
Blood. 2017 Oct 5;130(14):1620-1627
28983018
Pediatr Blood Cancer. 2015 Jun;62(6):1058-60
25400122
Blood. 1993 Aug 1;82(3):807-12
7687895
Int J Cancer. 2005 May 20;115(1):98-104
15688411
Ther Adv Hematol. 2015 Oct;6(5):228-41
26425336
Blood. 2013 Feb 14;121(7):1165-74
23243285
Curr Pharm Des. 2000 Dec;6(18):1841-79
11102565
Leuk Res. 2008 Dec;32(12):1849-56
18584865
Lancet Oncol. 2015 Jan;16(1):57-66
25524800
Am J Cancer Res. 2015 Jan 15;5(2):639-50
25973303
Mol Pharmacol. 2013 Jan;83(1):245-55
23093495
Leuk Lymphoma. 2012 Oct;53(10):1999-2003
22448921
Leukemia. 2012 Jul;26(7):1726-9
22358264
Leukemia. 2005 Jan;19(1):135; author reply 136
15510200
Biochim Biophys Acta. 2015 Jan;1853(1):254-63
25447675
Am J Clin Pathol. 2015 Sep;144(3):361-76
26276768
Blood. 2003 Sep 1;102(5):1578-82
12738663
Br J Haematol. 2013 Apr;161(1):27-42
23384118
Pharmacol Ther. 2012 Dec;136(3):334-42
22940266
Lancet. 2013 Jun 1;381(9881):1943-55
23523389
Future Oncol. 2015;11(12):1729-39
26075441
Blood. 2009 Jun 18;113(25):6330-7
18703706
Oncogene. 2007 May 28;26(25):3644-53
17530018
Cancer. 2006 Apr 1;106(7):1569-80
16502413
Nat Biotechnol. 2003 Jul;21(7):778-84
12778055
Mediterr J Hematol Infect Dis. 2014 Nov 01;6(1):e2014073
25408859
Future Oncol. 2014 May;10(7):1147-55
24947256
Clin Cancer Res. 2004 Aug 15;10(16):5327-34
15328168
J Clin Oncol. 2011 Jun 20;29(18):2493-8
21576633
Blood. 2012 Jul 12;120(2):285-90
22653976
J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41
19875969
Best Pract Res Clin Haematol. 2016 Mar;29(1):133
27742067
Blood. 2012 Dec 20;120(26):5185-7
23024237
J Clin Oncol. 2008 Aug 1;26(22):3756-62
18669463
Sci Transl Med. 2012 Aug 22;4(148):148rv9
22914624
Blood. 2015 Jan 22;125(4):680-6
25468567
EBioMedicine. 2015 May 05;2(6):486
26288809
Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8
21030349
J Cancer Ther. 2014 Jan;5(1):124-131
24851191
N Engl J Med. 2013 Apr 18;368(16):1509-1518
23527958
Semin Diagn Pathol. 2012 Feb;29(1):2-11
22372201
Nat Rev Clin Oncol. 2013 May;10(5):267-76
23546520
Hematology Am Soc Hematol Educ Program. 2010;2010:21-9
21239766
Science. 1975 Sep 19;189(4207):1002-5
1241159
N Engl J Med. 2014 Sep 11;371(11):1005-15
25207766